Eric Low

2.0k total citations
24 papers, 1.1k citations indexed

About

Eric Low is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Eric Low has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 14 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Eric Low's work include Multiple Myeloma Research and Treatments (18 papers), Cancer Treatment and Pharmacology (7 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Eric Low is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), Cancer Treatment and Pharmacology (7 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Eric Low collaborates with scholars based in United Kingdom, United States and Netherlands. Eric Low's co-authors include Jenny Bird, Richard Soutar, Graham Jackson, A. T. Reece, Diana Samson, Helen Lucraft, Shirley D’Sa, Guy Pratt, John A. Snowden and Jennifer M. Bird and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Haematology.

In The Last Decade

Eric Low

22 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Low United Kingdom 11 864 496 422 197 116 24 1.1k
Jenny Bird United Kingdom 11 723 0.8× 376 0.8× 562 1.3× 222 1.1× 104 0.9× 18 1.0k
Cathy Allen Ireland 9 539 0.6× 328 0.7× 116 0.3× 103 0.5× 42 0.4× 17 1.0k
C. Tom Kouroukis Canada 18 383 0.4× 460 0.9× 252 0.6× 346 1.8× 71 0.6× 49 1.2k
H Frommhold Germany 16 795 0.9× 507 1.0× 196 0.5× 253 1.3× 45 0.4× 70 1.6k
Sacha Satram‐Hoang United States 16 189 0.2× 537 1.1× 262 0.6× 152 0.8× 37 0.3× 48 1.0k
Maria Teresa Petrucci Italy 23 1.7k 1.9× 1.1k 2.1× 1.2k 2.9× 322 1.6× 75 0.6× 63 1.9k
Hemant Malhotra India 17 430 0.5× 239 0.5× 100 0.2× 377 1.9× 31 0.3× 72 973
Joan J. Ryoo United States 10 572 0.7× 427 0.9× 476 1.1× 107 0.5× 13 0.1× 19 872
David Topolsky United States 15 337 0.4× 348 0.7× 83 0.2× 93 0.5× 125 1.1× 39 884
Paola Fazi Italy 24 1.7k 2.0× 392 0.8× 603 1.4× 378 1.9× 123 1.1× 78 2.3k

Countries citing papers authored by Eric Low

Since Specialization
Citations

This map shows the geographic impact of Eric Low's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Low with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Low more than expected).

Fields of papers citing papers by Eric Low

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Low. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Low. The network helps show where Eric Low may publish in the future.

Co-authorship network of co-authors of Eric Low

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Low. A scholar is included among the top collaborators of Eric Low based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Low. Eric Low is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Briggs, Andrew, John R. Schneider, Eric Low, et al.. (2024). An Attribution of Value Framework for Combination Treatments. Value in Health. 28(1). 72–80.
2.
Bridges, John F. P., Esther W. de Bekker‐Grob, Brett Hauber, et al.. (2023). A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force. Value in Health. 26(2). 153–162. 32 indexed citations
3.
Heaney, Jennifer, Gulnaz Iqbal, Janet Dunn, et al.. (2020). Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study. SHILAP Revista de lepidopterología. 7(10). 1–70. 2 indexed citations
4.
Atkin, Catherine, Gulnaz Iqbal, Tim Planche, et al.. (2020). Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial. British Journal of Haematology. 192(6). 997–1005. 5 indexed citations
5.
Brown, Sarah, Charlotte Pawlyn, Louise Flanagan, et al.. (2020). Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. Clinical Lymphoma Myeloma & Leukemia. 21(3). 154–161.e3. 15 indexed citations
6.
Drayson, Mark T., Stella Bowcock, Tim Planche, et al.. (2019). Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. Health Technology Assessment. 23(62). 1–94. 4 indexed citations
7.
Postmus, Douwe, Nathalie Bere, Gert van Valkenhoef, et al.. (2017). Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma. The Oncologist. 23(1). 44–51. 43 indexed citations
8.
9.
Popat, Rakesh, Sarah Brown, Louise Flanagan, et al.. (2016). Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. The Lancet Haematology. 3(12). e572–e580. 35 indexed citations
10.
11.
12.
Low, Eric. (2015). POTENTIAL FOR PATIENTS AND PATIENT-DRIVEN ORGANIZATIONS TO IMPROVE EVIDENCE FOR HEALTH TECHNOLOGY ASSESSMENT. International Journal of Technology Assessment in Health Care. 31(4). 226–227. 4 indexed citations
13.
Yong, Kwee, Sarah Brown, Samantha Hinsley, et al.. (2015). Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen. Blood. 126(23). 1840–1840. 5 indexed citations
14.
Rabin, Neil, Simon Lai, Guy Pratt, et al.. (2014). United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma. International Journal of Laboratory Hematology. 36(6). 665–675. 1 indexed citations
15.
16.
Snowden, John A., Sam H. Ahmedzai, John Ashcroft, et al.. (2011). Guidelines for supportive care in multiple myeloma 2011. British Journal of Haematology. 154(1). 76–103. 153 indexed citations
17.
Bird, Jennifer M., Roger G. Owen, Shirley D’Sa, et al.. (2011). Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology. 154(1). 32–75. 223 indexed citations
18.
19.
Low, Eric, et al.. (2007). Access to expensive drugs in the NHS: myths and realities for cancer patients. International Journal of Clinical Practice. 61(12). 2126–2129. 3 indexed citations
20.
Soutar, Richard, Helen Lucraft, Graham Jackson, et al.. (2004). Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. British Journal of Haematology. 124(6). 717–726. 287 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jenny Bird Breakdown of academic impact, for papers by Cathy Allen Breakdown of academic impact, for papers by C. Tom Kouroukis Breakdown of academic impact, for papers by H Frommhold Breakdown of academic impact, for papers by Sacha Satram‐Hoang Breakdown of academic impact, for papers by Maria Teresa Petrucci Breakdown of academic impact, for papers by Hemant Malhotra Breakdown of academic impact, for papers by Joan J. Ryoo Breakdown of academic impact, for papers by David Topolsky Breakdown of academic impact, for papers by Paola Fazi
Rankless by CCL
2026